GlassScriptPhysician profile
Julia A Schroeder
NPI 1013901040
$694.54
in general payments reported to CMS, 2019-2025
10 companies · $132 in 2025
The $132 reported for 2025 was more than what a typical Addiction Medicine (Preventive Medicine) provider received nationally (typical 2025 total: $115).
See the full distribution for Addiction Medicine (Preventive Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $59.54 · 2023: $190 · 2024: $314 · 2025: $132.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $635.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $635.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braeburn INC. | $199.88 | 2023-2025 | Brixadi |
| Abbvie INC. | $159.28 | 2023-2025 | Vraylar |
| Indivior INC. | $133.35 | 2023-2024 | Sublocade |
| Orexo US, INC. | $43.43 | 2022-2023 | Zubsolv |
| Hikma Pharmaceuticals USA | $35.00 | 2022 | |
| Vanda Pharmaceuticals INC. | $34.37 | 2025 | Fanapt, Hetlioz |
| Uswm, LLC | $31.76 | 2023 | Zimhi, Lucemyra |
| Lundbeck LLC | $22.13 | 2024 | Rexulti |
| Neurocrine Biosciences, INC. | $19.47 | 2024 | Ingrezza |
| Tris Pharma INC | $15.87 | 2024 | Dyanavel Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Schroeder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.